Pular para o conteúdo
Merck
Todas as fotos(1)

Key Documents

Outros documentos

50359

Sigma-Aldrich

Voglibose

≥97.0% (TLC)

Sinônimo(s):

3,4-Dideoxy-4-{[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-2-D-epi-inositol, N-(1,3-Dihydroxyprop-2-yl)valiolamine

Faça loginpara ver os preços organizacionais e de contrato
Todas as fotos(1)

About This Item

Fórmula empírica (Notação de Hill):
C10H21NO7
Número CAS:
83480-29-9
Peso molecular:
267.28
Número MDL:
MFCD00865496
Código UNSPSC:
12352201
ID de substância PubChem:
329757591
NACRES:
NA.25

fonte biológica

synthetic

Nível de qualidade

100

Ensaio

≥97.0% (TLC)

forma

powder

cor

white

temperatura de armazenamento

−20°C

cadeia de caracteres SMILES

OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O

InChI

1S/C10H21NO7/c12-2-5(3-13)11-6-1-10(18,4-14)9(17)8(16)7(6)15/h5-9,11-18H,1-4H2/t6-,7-,8+,9-,10-/m0/s1

chave InChI

FZNCGRZWXLXZSZ-CIQUZCHMSA-N

Informações sobre genes

human ... GAA(2548) , MGAM(8972) , MGAM2(93432) , SI(6476)

Aplicação

Voglibose is an α-glucosidase inhibitor, similar to acarbose and miglitol, used for lowering post-prandial hyperglycemia (PPHG) in people with diabetes mellitus. Voglibose is used to study it benefits as a protectant against ischemia-reperfusion injury through glucagon-like peptide 1 receptors and the phosphoinositide 3-kinase-Akt-endothelial nitric oxide synthase pathway.

Embalagem

Bottomless glass bottle. Contents are inside inserted fused cone.

Outras notas

To gain a comprehensive understanding of our extensive range of Monosaccharides for your research, we encourage you to visit our Carbohydrates Category page.

Código de classe de armazenamento

11 - Combustible Solids

Classe de risco de água (WGK)

WGK 3

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable

Equipamento de proteção individual

Eyeshields, Gloves, type N95 (US)

Certificados de análise (COA)

Busque Certificados de análise (COA) digitando o Número do Lote do produto. Os números de lote e remessa podem ser encontrados no rótulo de um produto após a palavra “Lot” ou “Batch”.

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Os clientes também visualizaram

Slide 1 of 5

1 of 5

Monensin sodium salt 90-95% (TLC)

Sigma-Aldrich

M5273

Monensin sodium salt

Polivinilpirrolidona mol wt (number average molecular weight Mn 360kDa)

Sigma-Aldrich

PVP360

Polivinilpirrolidona

α-Glucosidase from Saccharomyces cerevisiae recombinant, expressed in proprietary host, lyophilized powder, ≥100 units/mg protein

Sigma-Aldrich

G0660

α-Glucosidase from Saccharomyces cerevisiae

Fosfato de sódio BioUltra, for molecular biology, ≥99.0% (T)

Sigma-Aldrich

71643

Fosfato de sódio

Sulfato de amônio for molecular biology, ≥99.0%

Sigma-Aldrich

A4418

Sulfato de amônio

Y Iwamoto et al.
Diabetes, obesity & metabolism, 12(8), 700-708 (2010-07-02)
To confirm the efficacy of vildagliptin in patients with type 2 diabetes (T2D) by testing the hypothesis that glycosylated haemoglobin (HbA1c) reduction with vildagliptin is superior to that with voglibose after 12 weeks of treatment. In this 12-week, randomized, double-blind
Clement Lo et al.
The Cochrane database of systematic reviews, 9, CD011798-CD011798 (2018-09-25)
Diabetes is the commonest cause of chronic kidney disease (CKD). Both conditions commonly co-exist. Glucometabolic changes and concurrent dialysis in diabetes and CKD make glucose-lowering challenging, increasing the risk of hypoglycaemia. Glucose-lowering agents have been mainly studied in people with
Bum-Ho Bin et al.
Experimental dermatology, 22(8), 541-546 (2013-07-25)
Overproduction of melanin can lead to medical disorders such as postinflammatory melanoderma and melasma. Therefore, developing antimelanogenic agents is important for both medical and cosmetic purposes. In this report, we demonstrated for the first time that the antidiabetic drug voglibose
R Kawamori et al.
Diabetes, obesity & metabolism, 14(4), 348-357 (2011-12-08)
To evaluate the efficacy and safety of linagliptin 5 and 10 mg vs. placebo and voglibose in Japanese patients with type 2 diabetes mellitus (T2DM). This study enrolled patients with inadequately controlled T2DM who were previously treated with one or
E Araki et al.
Diabetes, obesity & metabolism, 15(4), 364-371 (2012-11-21)
In a phase III study conducted among Japanese patients with type 2 diabetes mellitus (T2DM), linagliptin 5 and 10 mg showed clinically meaningful improvements in glycaemic parameters after 12 and 26 weeks compared with placebo and voglibose, respectively. This extension study assessed
Exibir todos os documentos relacionados

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica